Loading stock data…
$50.38-0.98 (-1.91%)
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States.
Bright Minds Biosciences Inc. in the Healthcare sector is trading at $52.43 with a market capitalization of $513M. Wall Street consensus targets $151.84 (6 analysts), implying a +189.6% move over the next 12 months. The stock is currently near its 52-week low of $47.23, remaining 30.3% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$11.43M↑ | -$15.32M↓ | -$6.90M↓ | -$5.66M↓ | -$3.30M |
| Net Income | -$2.40M↑ | -$10.46M↓ | -$7.57M↓ | -$4.09M↑ | -$5.24M |
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epile...